Serious and Progressive Neuropathy Presumably Post-Shingrix Vaccination
Reports, 2023 We present a case of serious and progressive neuropathy shortly following the administration of the herpes zoster subunit (HZ/su) vaccine, otherwise known as Shingrix.
Michael Wons +2 more
exaly +6 more sources
Prolonged Neurological and Musculoskeletal Symptoms Following Shingrix Vaccination
ReportsBackground and Clinical Significance: The recombinant zoster vaccine (Shingrix) helps prevent shingles and its complications in adults 50 and older. While minor side effects are common, severe adverse reactions are thought to be rare, and long-term side ...
Amna Khalid +2 more
exaly +6 more sources
Real-world data on the use of the Shingrix vaccine among patients with inflammatory arthritis and risk of cardiovascular events following herpes zoster [PDF]
Arthritis Research and TherapyBackground Risk of cardiovascular events may increase after herpes zoster; therefore, American College of Rheumatology guidelines strongly recommend vaccination against herpes zoster in patients aged ≥ 18 years with rheumatic and musculoskeletal diseases
, Kevin L Winthrop, Curtis Jeffrey R
exaly +4 more sources
Reactivation of Herpes Zoster Keratitis Following Shingrix Vaccine [PDF]
Case Reports in Ophthalmology, 2022 We present a case of herpes zoster keratitis reactivation shortly following the Shingrix vaccine. In our patient, reactivation of herpes zoster keratitis occurred a few weeks following the herpes zoster subunit (HZ/su) vaccine.
Tracy J. Lu, Christopher N. Ta
doaj +3 more sources
Predictors of initiation and completion of Shingrix vaccination in immunocompetent adults newly eligible for vaccination from 2018–2024 [PDF]
Human Vaccines & ImmunotherapeuticsThe Shingrix vaccine has been recommended for immunocompetent adults aged ≥50 y since October 2017. It is important to assess recent trends and predictors of Shingrix vaccination among those newly eligible to evaluate acceptability, desirability, and ...
Nina B. Masters +3 more
doaj +2 more sources
A single-dose mRNA vaccine induces potent and long-lasting humoral and cellular immunity against the varicella-zoster virus in a murine model [PDF]
Frontiers in ImmunologyIntroductionHerpes zoster is an infectious disease caused by the varicella-zoster virus (VZV). In adults, the reactivation of VZV can lead to severe neuralgia and skin rashes.
Wenyu Cheng +5 more
doaj +2 more sources
Recombinant Zoster Vaccine (Shingrix): a nex gun for Rheumatologist [PDF]
Beyond Rheumatology, 2022 Herpes Zoster, or as commonly known shingles, is a debilitating painful rash occurring at any age in anyone caused by reactivation of the varicella zoster virus (VZV). The lifetime risk of HZ in the general population is around 30% HZ incidence increases
D. Marotto, P. Sarzi Puttini, A. Riva
doaj +2 more sources
Uveitis Sarcoidosis Presumably Initiated After Administration of Shingrix Vaccine [PDF]
Cureus, 2019 Uveitis is a form of intraocular inflammation that can occur as a result of infection, injury, vaccination, or as a systemic manifestation of autoimmune or inflammatory diseases including sarcoidosis. Sarcoidosis is an inflammatory disease that involves the formation of abnormal granulomas in multiple organ systems. The hallmark of sarcoidosis is a non-
Heydari-Kamjani, Milad +4 more
exaly +3 more sources
Bullous fixed drug eruption following administration of the recombinant adjuvant Shingrix vaccine [PDF]
BMJ Case Reports, 2021 A 51-year-old woman with Crohn’s disease presented with a bullous rash on her left arm and axilla 2 days after receiving her second dose of the recombinant adjuvant Shingrix vaccine. PCR for herpes simplex virus (HSV) 1, HSV 2 and varicella zoster virus was negative. Punch biopsy revealed changes that were consistent with a bullous fixed drug eruption.
Laura Nichols
exaly +3 more sources
A modular nanoparticle display strategy for varicella-zoster virus gE based on a licensed protein scaffold. [PDF]
PLoS PathogensVaricella-zoster virus (VZV), the cause of shingles, remains a significant health issue worldwide, particularly among aging populations. The recombinant zoster vaccine (Shingrix, RZV) is the only approved vaccine in many countries and has demonstrated ...
Wenhui Xue +19 more
doaj +2 more sources